scholarly journals Electrochemotherapy and Other Clinical Applications of Electroporation for the Targeted Therapy of Metastatic Melanoma

Materials ◽  
2021 ◽  
Vol 14 (14) ◽  
pp. 3985
Author(s):  
Corina Ioana Cucu ◽  
Călin Giurcăneanu ◽  
Liliana Gabriela Popa ◽  
Olguța Anca Orzan ◽  
Cristina Beiu ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
High Efficiency ◽  
Skin Neoplasms ◽  
Clinical Applications ◽  
Clinical Indication ◽  
Safe Procedure ◽  
Primary Tumors ◽  
Reversible Electroporation ◽  
Oncologic Patients

Electrochemotherapy (ECT) is an effective bioelectrochemical procedure that uses controlled electrical pulses to facilitate the increase of intracellular concentration of certain substances (electropermeabilization/ reversible electroporation). ECT using antitumor drugs such as bleomycin and cisplatin is a minimally invasive targeted therapy that can be used as an alternative for oncologic patients not eligible for surgery or other standard therapies. Even though ECT is mainly applied as palliative care for metastases, it may also be used for primary tumors that are unresectable due to size and location. Skin neoplasms are the main clinical indication of ECT, the procedure reporting good curative results and high efficiency across all tumor types, including melanoma. In daily practice, there are many cases in which the patient’s quality of life can be significantly improved by a safe procedure such as ECT. Its popularity must be increased because it has a safe profile and minor local adverse reactions. The method can be used by dermatologists, oncologists, and surgeons. The aim of this paper is to review recent literature concerning electrochemotherapy and other clinical applications of electroporation for the targeted therapy of metastatic melanoma.

scholarly journals Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2978
Author(s):  
Chia-Jung Li ◽  
Yen-Dun Tony Tzeng ◽  
Yi-Han Chiu ◽  
Hung-Yu Lin ◽  
Ming-Feng Hou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
High Efficiency ◽  
Early Recurrence ◽  
New Developments ◽  
Great Progress ◽  
Low Toxicity ◽  
Made In

Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early recurrence, high invasion, and poor prognosis. Currently, its treatment includes chemotherapy, which shows a suboptimal efficacy. However, with the increasing studies on TNBC subtypes and tumor molecular biology, great progress has been made in targeted therapy for TNBC. The new developments in the treatment of breast cancer include targeted therapy, which has the advantages of accurate positioning, high efficiency, and low toxicity, as compared to surgery, radiotherapy, and chemotherapy. Given its importance as cancer treatment, we review the latest research on the subtypes of TNBC and relevant targeted therapies.

scholarly journals Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype

2014 ◽  
Vol 5 (3) ◽  
pp. 264-273 ◽  
Author(s):  
Kim H.T. Paraiso ◽  
Meghna Das Thakur ◽  
Bin Fang ◽  
John M. Koomen ◽  
Inna V. Fedorenko ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma

Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy

2021 ◽  
Vol 31 (3) ◽  
pp. 272-276
Author(s):  
Jens Tijtgat ◽  
Julia Katharina Schwarze ◽  
Gil Awada ◽  
Bart Neyns ◽  
Sandrine Aspeslagh
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Melanoma Patient ◽  
Braf V600e ◽  
Metastatic Melanoma Patient

Experience in using Topicream soothing cream CICA for rehabilitation of skin and mucous membranes after destructive dermatocosmetological procedures in combination therapy of dermatoses

2021 ◽  
pp. 33-38
Author(s):  
L.V. Hrechanska ◽  
O.V. Podluzhna ◽  
S.Р. Ostapenko ◽  
А.Е. Alatorskyh
Keyword(s):  
Clinical Practice ◽  
High Efficiency ◽  
Skin Diseases ◽  
Secondary Infection ◽  
Skin Neoplasms ◽  
Skin Surface ◽  
Punch Biopsy ◽  
Duration Of Treatment ◽  
Inflammatory Reactions ◽  
Mucous Membranes

The widespread introduction of the destructive methods of treatment into the clinical practice of dermatovenerologists is caused by the significant spread of benign skin and mucous neoplasms. At the same time, any effect on the skin — chemical, physical or mechanical — causes damage. Thus, patients using these procedures need proper care for damaged skin and mucous membranes to prevent secondary infection and scaring. Disruption of the epidermal barrier after removal of benign skin neoplasms, carrying out biopsy and chemical peels always requires application of topical agents promoting full recovery of the epidermis. In addition, many skin diseases are accompanied by inflammatory reactions, which are complicated by secondary infection. The use of drugs with anti­inflammatory and reparative properties reduces the duration of treatment and promotes skin recovery.Objective — to evaluate the clinical efficacy and tolerability of using Topicream soothing cream CICA after derma­tocosmetological procedures on the skin and mucous membranes and to investigate the efficacy of its use at various skin and mucous membranes diseases including children.Materials and methods. The study included 57 patients aged 1 to 75 years with various skin diseases, benign skin and mucosal neoplasms, after punch biopsy and cosmetology procedures. Topical application of the Topicream soothing cream CICA on the damaged skin and mucosal areas was recommended to all participants of the study twice a day. Results and discussion. The use of the regenerating cream after dermatological treatment of benign skin neoplasms with apparatus methods, chemical peelings and punch biopsy, as well as the auxiliary treatment of skin diseases such as cheilitis, herpes, perianal fissure, allergic contact dermatitis (including in children) localized in folds and on the face, contributes to a significant reduction in signs of inflammation and subjective sensations, as well as rapid healing of the affected skin surface. At the same time, there is a good tolerance and the absence of side effects of Topicream soothing cream CICA, which allows it to be widely used in clinical dermatovenerology, gynecology and pediatrics.Conclusions. High efficiency and safety of Topicream soothing cream CICA allow its widespread use in clinical practice of dermatovenerologists, gynecologists and pediatricians.

scholarly journals Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

2019 ◽  
Vol 10 ◽  
Author(s):  
Chune Yu ◽  
Xiaowei Liu ◽  
Jiqiao Yang ◽  
Min Zhang ◽  
Hongyu Jin ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Theory And Practice

scholarly journals Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma

2020 ◽  
Vol 33 (3) ◽  
pp. 390-402 ◽  
Author(s):  
Patricia M. LoRusso ◽  
Kurt Schalper ◽  
Jeffrey Sosman
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma

scholarly journals Targeted Therapy against Metastatic Melanoma Based on Self-Assembled Metal-Phenolic Nanocomplexes Comprised of Green Tea Catechin

2019 ◽  
Vol 6 (5) ◽  
pp. 1801688 ◽  
Author(s):  
Ke Li ◽  
Gao Xiao ◽  
Joseph J. Richardson ◽  
Blaise L. Tardy ◽  
Hirotaka Ejima ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Green Tea ◽  
Green Tea Catechin ◽  
Self Assembled

Frontline Therapy forBRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?

2019 ◽  
pp. 564-571 ◽  
Author(s):  
Anna C. Pavlick ◽  
Leslie Fecher ◽  
Paolo A. Ascierto ◽  
Ryan J. Sullivan
Keyword(s):  
Targeted Therapy ◽  
Metastatic Melanoma ◽  
Initial Therapy ◽  
Combination Immunotherapy ◽  
Wild Type ◽  
Aggressive Disease ◽  
Multiple Factors ◽  
Secondary Endpoints ◽  
Frontline Therapy ◽  
Mutation Braf

Genetic analysis of melanoma has allowed us to identify a population of patients who have more aggressive disease and harbor the driver mutation BRAF. This mutation is found in approximately 50% of metastatic disease and provides a target for focused therapies to control this disease. These responses are usually brisk; however, they lack the durability of immunotherapy. Frontline therapy for patients with BRAF-mutated melanoma is not as straightforward as prescribing BRAF/MEK inhibitors. Prior trials of combination immunotherapy demonstrate similar responses and durability of responses in patients with BRAF wild-type as well as BRAF-mutated disease. Decisions about immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy require an oncologist to evaluate multiple factors to select which treatment option is best for the patient. Trials for metastatic melanoma have included biomarkers as secondary endpoints and aim to identify some way to predict a response, or lack thereof, to therapy. Here, we discuss the utility and reliability of biomarkers in determining therapy for patients with BRAF-mutated metastatic melanoma and discuss combination immunotherapy with targeted therapy versus sequential immunotherapy/targeted therapy as well as which regimen should be implemented as initial therapy.

Sign in / Sign up

Export Citation Format

Share Document